Market closedNon-fractional
Precigen/PGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Precigen
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Ticker
PGEN
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Germantown, United States
Employees
202
Website
precigen.com
Precigen Metrics
BasicAdvanced
$371M
Market cap
-
P/E ratio
-$0.39
EPS
1.88
Beta
-
Dividend rate
Price and volume
Market cap
$371M
Beta
1.88
Financial strength
Current ratio
1.722
Quick ratio
1.596
Long term debt to equity
5.553
Total debt to equity
6.911
Interest coverage (TTM)
-615.45%
Management effectiveness
Return on assets (TTM)
-29.84%
Return on equity (TTM)
-68.94%
Valuation
Price to revenue (TTM)
67.406
Price to book
3.8
Price to tangible book (TTM)
11.61
Price to free cash flow (TTM)
-5.363
Growth
Revenue change (TTM)
-76.60%
Earnings per share change (TTM)
-432.52%
3-year revenue growth
-58.62%
3-year earnings per share growth
-19.42%
What the Analysts think about Precigen
Analyst Ratings
Majority rating from 5 analysts.
Precigen Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
-16.67%
Net income
-$24M
-28.18%
Profit margin
-2,370.00%
-13.82%
Precigen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.08
-$0.13
-$0.10
-
Expected
-$0.10
-$0.08
-$0.08
-$0.09
-$0.09
Surprise
-20.00%
2.56%
67.74%
14.16%
-
Precigen News
AllArticlesVideos
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
PRNewsWire·1 month ago
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
PRNewsWire·1 month ago
Precigen Reports First Quarter 2024 Financial Results and Business Updates
PRNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precigen stock?
Precigen (PGEN) has a market cap of $371M as of July 06, 2024.
What is the P/E ratio for Precigen stock?
The price to earnings (P/E) ratio for Precigen (PGEN) stock is 0 as of July 06, 2024.
Does Precigen stock pay dividends?
No, Precigen (PGEN) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Precigen dividend payment date?
Precigen (PGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Precigen?
Precigen (PGEN) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Precigen stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.